Literature DB >> 2253658

Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects.

A Fujimura1, A Ebihara.   

Abstract

The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study. Furosemide 20 mg was injected intravenously in eight hypertensive subjects already treated with oral captopril 25 mg or a matching placebo. Urinary excretion of 6-keto-PGF1 alpha (a metabolite of PGI2) and PGE2, PRA and AII was increased following furosemide without captopril pretreatment. The rises in urinary 6-keto-PGF1 alpha and PGE2, and plasma AII after furosemide were prevented by the captopril pretreatment. Urinary volume, sodium and furosemide were not affected by captopril. The data indicate that the effect of furosemide on PGI2 production, as reflected by the urinary excretion of 6-keto-PGF1 alpha, was mediated by an action of AII.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253658     DOI: 10.1007/bf00280042

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.

Authors:  I De Lepeleire; A Van Hecken; R Verbesselt; G Kaiser; A Barner; I Holmes; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  [A method for radioimmunoassay of plasma angiotensin II using florisil].

Authors:  T Morimoto; M Aoyama; E Gotoh; H Shionoiri
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1983-03-20

4.  Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.

Authors:  A Rakhit; G M Kochak; V Tipnis; M E Hurley
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

5.  Separation and quantitative analysis of furosemide and 4-chloro-5-sulfamoylanthranilic adid (CSA) by high pressure liquid chromatography.

Authors:  M L MacDougall; D W Shoeman; D L Azarnoff
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-02

6.  Role of angiotensin II in renal prostaglandin E2 production after furosemide administration.

Authors:  A Fujimura; A Ebihara
Journal:  Hypertension       Date:  1988-05       Impact factor: 10.190

7.  Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1 alpha formation by isolated human glomeruli.

Authors:  R A Stahl; M Paravicini; P Schollmeyer
Journal:  Kidney Int       Date:  1984-07       Impact factor: 10.612

8.  Time-dependent changes in prostaglandin excretion in response to frusemide in man.

Authors:  B Scherer; P C Weber
Journal:  Clin Sci (Lond)       Date:  1979-01       Impact factor: 6.124

Review 9.  Arachidonic acid metabolism, prostaglandins and the kidney.

Authors:  D J Levenson; C E Simmons; B M Brenner
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

10.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

Authors:  C Patrono; F Pugliese; G Ciabattoni; P Patrignani; A Maseri; S Chierchia; B A Peskar; G A Cinotti; B M Simonetti; A Pierucci
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

View more
  1 in total

1.  Combining salicylate and enalapril in patients with coronary artery disease and heart failure.

Authors:  L H Baur; J J Schipperheyn; A van der Laarse; J H Souverijn; M Frölich; A de Groot; P J Voogd; T F Vroom; V M Cats; M J Keirse
Journal:  Br Heart J       Date:  1995-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.